Why McDermott International (MDR) Is Down on Tuesday

NEW YORK (TheStreet) -- Oil industry engineer McDermott International (MDR) opened Tuesday's session lower after posting below-consensus quarterly earnings and sales after the bell Monday

By market open, shares had taken off 7.3% to $7.51. Trading volume of 9.5 million was more than double its three-month daily average. 

The Houston-based business recorded a net loss of $1.37 a share in its fourth quarter. Analysts polled by Thomson Reuters had forecast net income of 15 cents a share. 

Management also suspended guidance for the foreseeable future until it can implement organizational changes.

Also See: Ford, GM Shares Buoyed by Hopes For March

Tuesday Fun-One: From Brands to Blockbusters: 17 Winners and Losers

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates MCDERMOTT INTL INC as a Sell with a ratings score of D+. The team has this to say about their recommendation:

"We rate MCDERMOTT INTL INC (MDR) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself."

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing